|
|
 |
 |
| |
 Printable version |
Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts |
European Journal of Dermatology. Volume 16, Number 6, 642-8, November-December 2006, Therapy
|
 Free Article
|
Author(s) : Helmut Schöfer, Arndt Van Ophoven, Ulrike Henke, Tamara Lenz, Angelika Eul |
Summary : Conventional ablative treatments for external anogenital warts are affected by high recurrence rates. This study compared sustained clearance after ablation vs. treatment with imiquimod 5% cream vs. the combination of both methods. This was a 3-arm, open-label, randomized clinical study comparing ablation alone (Group A), imiquimod 5% cream monotherapy (Group B), or combined ablation followed by topical imiquimod (Group C). Subjects whose anogenital warts were completely cleared entered a 6-month follow-up to evaluate sustained clearance.After 3 months follow-up, 83.9% (73/87), 93.8% (90/96) and 91.7% (66/72) of subjects in Groups A, B, C, respectively, remained free of recurrent anogenital warts. After 6–months follow-up, 73.6% (64/87), 93.7% (89/95) and 91.5% (65/71) of subjects presented free of recurrence (Group A vs. B &\; C p-values each p <\; 0.004 in favour of the imiquimod-treated groups).Imiquimod 5% cream, as monotherapy or in combination with ablation, was superior to ablation alone in reducing the recurrence of successfully treated anogenital warts. |
Keywords : ablative therapy, anogenital warts, comparative trial, imiquimod 5%, recurrence rate, sustained efficacy |
|
